Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
1.02x
JBCHEPHARM's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.
Free Cash Flow
₹8.05B
JBCHEPHARM's free cash flow was ₹8.05B in FY 2025, up 19.5% from FY 2024.
Dividend Coverage
3.4x
JBCHEPHARM's free cash flow covered dividends 3.4x in FY 2025, leaving room for reinvestment or debt reduction.
CapEx Intensity
10.8%
Capital expenditure was 10.8% of operating cash flow in FY 2025 for JBCHEPHARM, indicating a capital-light business.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 7.52B | 8.87B | |
| Cash flow Operating Activities | 8.01B | 9.02B | |
| Investments in PPE | -1.27B | -975.88M | |
| Cash flow Investing Activities | -4.04B | -2.96B | |
| Dividend Paid | -1.57B | -2.37B | |
| Cash flow Financing Activities | -3.85B | -5.80B | |
| Cash at beginning of period | 769.34M | 882.15M | |
| Cash at end of period | 882.15M | 1.15B | |
| Free Cash Flow | 6.74B | 8.05B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025